source
- Bambusa Therapeutics exceeds IPO target raising $169 million, while Aspen Neuroscience falls short with $141 millionBambusa Therapeutics announced that its initial public offering was upsized, selling more shares at the midpoint of its $15‑$17 range and raising about $168.9 million, exceeding the $150.4 million…
- Acumen scraps sole asset after Alzheimer’s fail, plunging stock 80%Acumen will implement cash-saving strategies and assess its options after sabirnetug failed to beat placebo, leaving the biotech without a clinical program.